PRISYM ID Makes New Senior Appointment to Drive Further Growth in Clinical Trials Arena


Wokingham, United Kingdom — 4 September 2020 — PRISYM ID, a leading provider of regulated content and label management solutions, has announced the appointment of Robert Bowdish as Director of Clinical Trials Sales for North America.

Robert has wide-ranging healthcare industry sales experience. Having started out working as a pharmaceutical sales representative 26 years ago, he has been specializing in the regulatory and clinical software solutions and services market for the past decade.

He has joined PRISYM ID from Parexel Informatics, where he was initially appointed Senior Director for Solutions Consulting and then became Senior Director for Regulatory Clinical Solutions, Global Sales, where he led a team of sales directors working across diverse sectors.

Prior to that, he worked as a Senior Account Executive for Truven Health Analytics, which was acquired by IBM Watson Health.

Other posts that Robert has held include Regional Sales Director for Takeda Pharmaceuticals in North America, leading a commercial team of 10 district managers and 100 sales representatives.

Warren Stacey, SVP of Sales at PRISYM ID, commented: “Robert Bowdish is a fantastic addition to our team at PRISYM ID. He will take the lead driving Clinical Trials Sales in the North American market, building on his relationships with pharma and CROs, demonstrating how our market-leading products can be integrated into a clinical trial supply chain to deliver a compliant labeling solution.”

About the Company:

PRISYM ID provides regulated content and label management solutions designed specifically for life science companies and medical device manufacturers, improving patient safety and health outcomes whilst ensuring regulatory compliance. With a focus on medical device manufacturing and clinical trial supplies, PRISYM ID’s unique products and technologies are used to assure compliance globally, for 10 million+ medical devices and pharmaceutical products annually.

For more information:

Andrew Baud, Distil,, +44 (0) 7775 715775